StressMarq Biosciences, a market leader in products for neurodegenerative disease research, and Luxembourg-based OrganoTherapeutics, are pleased to announce a new collaboration dedicated to furthering Parkinson’s disease research through the study of alpha synuclein pathology in midbrain organoids.

The collaboration between StressMarq and OrganoTherapeutics will focus on the establishment of an RT-QuIC assay for alpha synuclein amplification in organoid models, utilizing StressMarq’s unique portfolio of alpha synuclein monomer, oligomer, and fibril preparations.

Dr. Gemma Gómez Giró, OrganoTherapeutics research project leader, remarks that “[She is] excited to start this collaboration,” as the RT-QuIC assay, while becoming increasingly relevant for diagnostic purposes in Parkinson’s disease patients, has never been tested in organoids. “The products and expertise from StressMarq will be crucial to guide us into succeeding when implementing this assay,” concludes Dr. Gómez Giró.

StressMarq is committed to providing high-quality, innovative products to assist researchers studying Parkinson’s disease and other neurodegenerative diseases. Through the use of proprietary, human-specific, 3D in vitro models, OrganoTherapeutics’ midbrain organoids faithfully mimic Parkinson’s disease pathology in humans, facilitating unique opportunities for the discovery and development of effective drug candidates in the treatment of PD.

About StressMarq Biosciences:

Established in 2007, StressMarq Biosciences Inc. is a Canadian-based company that produces bioreagents and cutting-edge research products for the life sciences and drug discovery research markets. With the breadth and depth of their product portfolio of alpha synuclein, tau, amyloid beta, SOD1 and TTR preparations, StressMarq has established itself as a market leader in the development of these unique neurodegenerative disease research products.

For more information visit: https://www.stressmarq.com/ 

About OrganoTherapeutics:

OrganoTherapeutics was founded in July 2019 as spin-off biotech from the University of Luxembourg / Luxembourg Centre for Systems Biomedicine. Using a human-specific, personalized, 3D in vitro model, their proprietary midbrain organoids are used to conduct research into the discovery and development of effective drug candidates, with a special interest in targeting neurodegeneration in Parkinson`s disease (PD) patients. OrganoTherapeutics focuses on deep phenotyping and phenotype-based drug screening, as well as artificial intelligence-assisted analysis.

For more information visit: www.organo-therapeutics.com